OverviewSuggest Edit
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.
| Type | Public | |
| Founded | 2001 | |
| HQ | South San Francisco, US | Map |
| Website | fiveprime.com | |
| Employee Ratings | More |
Key People/Management at Five Prime Therapeutics
Aron Knickerbocker
Francis Sarena
Jeff Coon
Helen Collins
Bryan Irving
Nallakkan S. Arvindan
Five Prime Therapeutics Office Locations
Five Prime Therapeutics Financials and Metrics
Five Prime Therapeutics Revenue
| USD | |
|---|---|
Net income (FY, 2018) | (140.4m) |
EBIT (FY, 2018) | (146.2m) |
Market capitalization (22-Mar-2019) | 463.8m |
Closing stock price (22-Mar-2019) | 13.1 |
Cash (31-Dec-2018) | 44.0m |
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 2.6m | 3.3m | 3.0m | 3.4m | 4.6m | 5.2m | 8.6b | 8.1b | 9.1m | 10.5m | 9.4m | 9.7m | 10.5m | 9.8m |
R&D expense | 8.2m | 8.9m | 11.9m | 9.8m | 13.3m | 24.7m | 18.3b | 22.2b | 23.9m | 33.8m | 41.7m | 42.7m | 43.6m | 33.4m |
Operating expense total | 10.8m | 12.2m | 14.9m | 13.2m | 17.9m | 29.9m | 26.9b | 30.3b | 33.0m | 44.2m | 51.1m | 52.4m | 54.0m | 43.2m |
EBIT | (7.3m) | (8.7m) | (9.9m) | (7.1m) | (11.6m) | (24.1m) | (20.4b) | (21.1b) | (26.4m) | (34.1m) | (43.3m) | (44.1m) | (21.5m) | (35.6m) |
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q3, 2015 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 77.6m | 11.7m | 13.1m | 13.1m | 37.0m | 56.4m | 47.2m | 59.7m | 36.4m | 65.9m | 52.8m |
Current Assets | 87.9m | 150.2m | 142.0m | 131.8m | 190.5m | 454.0m | 399.2m | 363.3m | 333.4m | 403.0m | 363.0m |
PP&E | 4.0m | 3.6m | 4.0m | 4.0m | 4.0m | 5.4m | 7.9m | 15.2m | 22.5m | 30.3m | 30.0m |
Total Assets | 92.0m | 154.3m | 146.4m | 136.3m | 195.0m | 465.1m | 409.1m | 380.1m | 357.4m | 436.7m | 396.8m |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.2 x |
Five Prime Therapeutics Online and Social Media Presence
Five Prime Therapeutics News and Updates
Five Prime Therapeutics Blogs
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26
Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum
Jonathan Chang
Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
Five Prime Therapeutics Frequently Asked Questions
When was Five Prime Therapeutics founded?
Five Prime Therapeutics was founded in 2001.
Who are Five Prime Therapeutics key executives?
Five Prime Therapeutics's key executives are Aron Knickerbocker, Francis Sarena and Jeff Coon.
How many employees does Five Prime Therapeutics have?
Five Prime Therapeutics has 168 employees.
Who are Five Prime Therapeutics competitors?
Competitors of Five Prime Therapeutics include Heat Biologics, Immune Design and Geron.
Where is Five Prime Therapeutics headquarters?
Five Prime Therapeutics headquarters is located at 2 Corporate Dr, South San Francisco.
Where are Five Prime Therapeutics offices?
Five Prime Therapeutics has an office in South San Francisco.
How many offices does Five Prime Therapeutics have?
Five Prime Therapeutics has 1 office.